Content about Savient Pharmaceuticals

September 24, 2012

Savient Pharmaceuticals has appointed a new finance chief.

BRIDGEWATER, N.J. — Savient Pharmaceuticals has appointed a new finance chief.

John Hamill will serve as Savient's SVP and CFO, where he will be responsible for all financial and accounting functions of the company. Hamill, who brings more 25 years of global financial and administrative operational experience to his new role, will directly report to Savient president and CEO Lou Ferrari. Prior to joining the drug maker, Hamill served as CFO of PharmaNet Development Group, a leading global supplier of drug development services.

February 1, 2012

A former Johnson & Johnson executive has been appointed to serve as interim CEO for Savient Pharmaceuticals.

EAST BRUNSWICK, N.J. — A former Johnson & Johnson executive has been appointed to serve as interim CEO for Savient Pharmaceuticals.

Savient's board of directors appointed David Norton to serve as interim CEO, succeeding current CEO John Johnson, who is leaving the company to become president, CEO and chairman-elect of biotechnology company Denderon. Savient's board said it will conduct a search process for a permanent CEO.

Norton, who is a member of Savient's board, formerly served as J&J company group chairman of global pharmaceuticals.

August 17, 2011

Patients with gout taking a drug made by Savient Pharmaceuticals experienced "significant" improvements, according to results of two late-stage clinical trials published in the Journal of the American Medical Association.

EAST BRUNSWICK, N.J. — Patients with gout taking a drug made by Savient Pharmaceuticals experienced "significant" improvements, according to results of two late-stage clinical trials published in the Journal of the American Medical Association.

February 17, 2011

Savient Pharmaceuticals announced changes to its management team as it gears up for the commercial launch of its chronic gout treatment.

EAST BRUNSWICK, N.J. — Savient Pharmaceuticals announced changes to its management team as it gears up for the commercial launch of its chronic gout treatment.

The drug maker appointed Louis Ferrari as its SVP corporate development, Christine Mikail as SVP and Stephen Davies as chief information officer and group VP.

December 1, 2010

Drug maker Savient Pharmaceuticals has begun shipping its new gout treatment to specialty distributors, the company said Tuesday.

EAST BRUNSWICK — Drug maker Savient Pharmaceuticals has begun shipping its new gout treatment to specialty distributors, the company said Tuesday.

Savient announced the shipment of Krystexxa (pegloticase), saying it would become available by prescription starting Wednesday.

The drug, designed for administration by IV, received approval on Sept. 14 from the Food and Drug Administration for treating chronic gout.

November 4, 2010

Drug maker Savient Pharmaceuticals will begin shipping its treatment for chronic gout to specialty distributors...

EAST BRUNSWICK, N.J. Drug maker Savient Pharmaceuticals will begin shipping its treatment for chronic gout to specialty distributors at the end of this month, Savient said.

The company announced that it would begin shipping Krystexxa (pegloticase) on Nov. 30, and it would become available for prescription on Dec. 1.

September 14, 2010

The Food and Drug Administration has approved a new treatment for gout, a painful condition...

WASHINGTON The Food and Drug Administration has approved a new treatment for gout, a painful condition that affects 3 million adults in the United States.

The FDA announced the approval of Savient Pharmaceuticals’ Krystexxa (pegloticase), a biotech drug for people who have not responded to or tolerated conventional therapies.